Search results for " Aggregation"

showing 10 items of 441 documents

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention …

2019

Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y 12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI,…

MaleVitamin Kmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicineAntithromboticAtrial Fibrillation//purl.org/pe-repo/ocde/ford#3.02.04 [https]030212 general & internal medicineProspective Studies610 Medicine & healthAspirinVKADisease ManagementAtrial fibrillationVitamin K antagonistMiddle AgedCombined Modality TherapyHospitalizationTreatment Outcomesurgical procedures operativeElective Surgical ProceduresCardiologyApixabanDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyAcute coronary syndromemedicine.drug_classPyridonesDOACHemorrhageP2Y12 inhibitor03 medical and health sciencesPercutaneous Coronary InterventionFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeAgedProportional Hazards ModelsAspirinbusiness.industryPercutaneous coronary interventionAnticoagulantsCardiovascular Agentsmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsPyrazolesbusinessPlatelet Aggregation Inhibitors
researchProduct

Formulation, process conditions, and biological evaluation of dairy mixed gels containing fava bean and milk proteins: Effect on protein retention in…

2019

International audience; Food formulation and process conditions can indirectly influence AA digestibility and bioavailability. Here we investigated the effects of formulation and process conditions used in the manufacture of novel blended dairy gels (called "mixed gels" here) containing fava bean (Vicia faba) globular proteins on both protein composition and metabolism when given to young rats. Three mixed dairy gels containing casein micelles and fava bean proteins were produced either by chemical acidification (A) with glucono-δ-lactone (GDL) or by lactic acid fermentation. Fermented gels containing casein and fava bean proteins were produced without (F) or with (FW) whey proteins. The AA…

MaleWhey proteinProtein efficiency ratioFood Handling[SDV]Life Sciences [q-bio]chemistry.chemical_compoundCaseinLeguminDenaturation (biochemistry)Food scienceAmino AcidsPlant Proteins2. Zero hunger0303 health sciencesChemistry[SDV.BA]Life Sciences [q-bio]/Animal biologyCaseinsfood and beverages04 agricultural and veterinary sciencesHydrogen-Ion ConcentrationMilk ProteinsLactic acidVicia fabaProtéines de fèvesDigestionDietary ProteinsNutritive ValueLactic acid fermentationQualité des protéines alimentairefava bean proteinBiological AvailabilitygelationMélange de protéinesprotein aggregation03 medical and health sciencesGélificationmilk proteinGeneticsAnimalsRats Wistar030304 developmental biology0402 animal and dairy sciencedietary protein quality040201 dairy & animal scienceRatsWhey ProteinsFermentationAnimal Science and ZoologyDairy ProductsProtéines du lait[SDV.AEN]Life Sciences [q-bio]/Food and NutritionProtein qualityGelsFood Science
researchProduct

Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina

2006

SummaryApplication of clopidogrel before percutaneous coronary intervention in patients with acute coronary syndrome reduces the risk of cardiac events. Clopidogrel administration before surgery increases bleeding complications after CABG. Therefore, the antithrombotic effect of the low-dose combination of clopidogrel and aspirin was investigated in an in vivo pig model of coronary artery thrombus formation with cyclic flow reductions. The platelet inhibitory effect was determined by platelet aggregation and CFR, according to the methodology described by Folts. CFR were initiated by endothelial damage and placement of a constrictor around the LAD. 30 min after CFR were established, clopidog…

Malemedicine.medical_specialtyAcute coronary syndromeTiclopidinePlatelet AggregationSwinemedicine.medical_treatmentAnginaInternal medicineAntithromboticmedicineAnimalsPlateletAngina Unstablecardiovascular diseasesAspirinAspirinbusiness.industryUnstable anginaCoronary ThrombosisPercutaneous coronary interventionHematologymedicine.diseaseClopidogrelClopidogrelDisease Models AnimalAcute DiseaseCardiologyDrug Therapy CombinationbusinessPlatelet Aggregation Inhibitorscirculatory and respiratory physiologymedicine.drugThrombosis and Haemostasis
researchProduct

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

2019

Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. Results: Enroll…

Malemedicine.medical_specialtyAcute coronary syndromeVitamin KPyridonesmedicine.medical_treatmentMEDLINEHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawInternal medicineAtrial FibrillationAntithromboticmedicineHumans03.02. Klinikai orvostancardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedAged 80 and overAspirinbusiness.industryatrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixabanAnticoagulantsPercutaneous coronary interventionAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsCardiologyPyrazolesDrug Therapy CombinationFemalebusinessPlatelet Aggregation InhibitorsFactor Xa InhibitorsNew England Journal of Medicine
researchProduct

Blood rheology effect of submaximal exercise on young subjects

2013

Nowadays cardiac and metabolic diseases are a matter of concern. Exercise is a valid treatment and method of prevention for not only adults, but also young subjects. Physical activity causes transient blood rheology impairment in adults. However little is known about the effects of exercise on blood flow characteristics in young subjects. The aim of the study was to assess the effects of a light aerobic exercise session on blood rheology in young subjects. Ten young subjects (aged 12-16 years) performed 1 hour of submaximal aerobic exercise (70% HRmax). Blood samples were drawn just before and after exercise. We determined blood and plasma viscosity, fibrinogen, erythrocyte deformability an…

Malemedicine.medical_specialtyAdolescentPhysiologyBlood viscosityHematocritFibrinogenErythrocyte aggregationPhysiology (medical)Internal medicinemedicineHumansAerobic exerciseErythrocyte deformabilityPlasma VolumeChildExercisemedicine.diagnostic_testbusiness.industryFibrinogenHematologyBlood flowHematocritHemorheologyCardiologyPhysical therapyFemaleHemorheologyCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsAntithrombin IIIAtrial AppendagePilot Projects030204 cardiovascular system & hematologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanLeft atrialHeart RateInternal medicineAtrial FibrillationMedicineHumansAtrial Appendage030212 general & internal medicineContraindicationBlood CoagulationAgedAppendageAged 80 and overRivaroxabanbusiness.industryDual Anti-Platelet TherapyAtrial fibrillationThrombosisClopidogrelmedicine.diseasePeptide Fragments3. Good healthTreatment OutcomeCardiologyAtrial Function LeftFemaleProthrombinFranceCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsPeptide HydrolasesCirculation. Cardiovascular interventions
researchProduct

Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation

2009

Background: Percutaneous closure of the left atrial appendage (LAA) is a novel alternative for the treatment of patients with atrial fibrillation (AF) and with a high risk of stroke who are not eligible for long-term anticoagulation therapy. The aim of this study was to asses the safety, feasibility, and long-term efficacy of this procedure. Methods: From July 2004 to June 2007, 20 patients (13 male, mean age 69 ± 8 years) with non–valvular AF (NV-AF) underwent LAA percutaneous closure using the PLAATO™ system, implanted through a transeptal access. All patients had contraindications to anticoagulant therapy and were at high risk for cardioembolic stroke (mean CHADS2 score 3 ± 1.2). A trans…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsThromboembolism.left atrial appendage occlusionmedicine.medical_treatmentEmbolismSettore MED/11 - Malattie dell'Apparato CardiovascolareTransesophagealLeft atrial appendage occlusionPericardial effusionRisk AssessmentLeft atrialInternal medicineAtrial FibrillationmedicineHumansRadiology Nuclear Medicine and imagingAtrial Appendageatrial fibrillation; left atrial appendage occlusion; thromboembolism; Aged; Atrial Fibrillation; Contraindications; Echocardiography Transesophageal; Embolism; Equipment Design; Feasibility Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Time Factors; Treatment Outcome; Anticoagulants; Atrial Appendage; Cardiac Catheterization; Chronic DiseaseStrokeAgedbusiness.industryContraindicationsAnticoagulantsAtrial fibrillationGeneral MedicineEquipment DesignthromboembolismMiddle Agedmedicine.diseaseSurgeryStrokeTreatment OutcomePericardiocentesisEchocardiographyChronic DiseaseCardiologyPatent foramen ovaleFeasibility StudiesFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealPlatelet Aggregation Inhibitors
researchProduct

The treatment of venous leg ulcers: a new therapeutic use of iloprost

2007

Background: We conducted a study using an intravenous (i.v.) infusion of iloprost in the treatment of venous ulcers to verify whether the association of i.v. iloprost + local therapy + elastic compression has a favorable effect when compared with traditional treatment with local therapy and elastic compression. Study Design: We evaluated the effects of iloprost in 98 consecutive patients with noncomplicated venous ulcers of lower limbs subdivided into 2 groups: the first group (48 patients) received iloprost in saline solution for 3 weeks and the second group (50 patients) received a venous infusion of a saline solution. The patients were examined at baseline time 0 (first visit) and then a…

Malemedicine.medical_specialtyElastic compressionmedicine.medical_treatmentIschemiaPlacebo groupDrug Administration Schedulelaw.inventionRandomized controlled triallawmedicineHumansSingle-Blind MethodIloprostInfusions IntravenousVeinSalineDose-Response Relationship Drugbusiness.industryvenous ulcersiloprostLeg UlcerSignificant differenceMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureDebridementAnesthesiaAnti-Infective Agents LocalFemaleSurgeryVENOUS LEG ULCERS ILOPROSTbusinessPlatelet Aggregation InhibitorsStockings CompressionIloprostmedicine.drug
researchProduct

The relationship between the rheological behavior of RBCs and angiogenesis in the morbidly obese

2018

OBJECTIVE The aim of this study was to investigate the relationship between red blood cell (RBC) aggregation and deformability and angiogenesis parameters in obese patients. METHODS We studied 35 obese subjects and 20 non-obese people as a control group. Angiogenesis was detected using Bio-Plex Pro Human Angiogenesis Multiplex Assays. The RBC aggregation and deformability of the red blood cell aggregation were performed by the Laser-assisted Optical Rotational Cell Analyser - LORCA. RESULTS The aggregation index and the syllectogram's amplitude were significantly higher in the obese patients, whereas the aggregation half-time (t1/2) was lower compared with the control group. The deformabili…

Malemedicine.medical_specialtyErythrocytesPhysiologyAngiogenesisVEGF receptors030204 cardiovascular system & hematologyMorbidly obeseIndependent predictor030218 nuclear medicine & medical imagingCardiovascular Physiological Phenomena03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineObese groupHumansMedicinebiologybusiness.industryAngiopoietin 2HematologyObesity MorbidRed blood cell aggregationRed blood cellmedicine.anatomical_structureEndocrinologybiology.proteinFemaleRheologyCardiology and Cardiovascular MedicinebusinessClinical Hemorheology and Microcirculation
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct